Table 1.
Correlation between GSTA1 and clinicopathologic features in 90 HCC patients
| Variable (missing cases) | Cases | GSTA1 | P-value | ||
|---|---|---|---|---|---|
| Low | Moderate | High | |||
| Gender | 0.524 | ||||
| Female | 20(22.2%) | 7(35.0%) | 7(35.0%) | 6(30.0%) | |
| Male | 70(77.8%) | 14(20.0%) | 37(52.8%) | 19(27.2%) | |
| Age/year | 0.271 | ||||
| ≤ 50 | 40(44.4%) | 12(30.0%) | 18(45.0%) | 10(25.0%) | |
| >50 | 50(55.6%) | 9(18.0%) | 26(52.0%) | 15(30.0%) | |
| HBsAg | 0.928 | ||||
| Negative | 19(21.1%) | 8(42.1%) | 9(47.4%) | 2(10.5%) | |
| Positive | 71(78.9%) | 13(11.2%) | 35(26.4%) | 23(43.1%) | |
| Preoperative AFP | 0.026* | ||||
| ≤ 400 ng/mL | 56(62.2%) | 7(12.5%) | 32(57.1%) | 17(30.4%) | |
| >400 ng/mL | 34(37.8%) | 14(41.2%) | 12(35.3%) | 8(23.5%) | |
| Tumor Number | 0.055 | ||||
| Single | 77(86.6%) | 16(20.8%) | 37(48.0%) | 24(31.2%) | |
| Multiple | 13(13.4%) | 5(38.5%) | 7(53.8%) | 1(7.7%) | |
| Tumor size | 0.307 | ||||
| ≤ 3 cm | 32(35.6%) | 5(15.6%) | 17(53.1%) | 10(31.3%) | |
| 3-5 cm | 22(24.4%) | 6(27.3%) | 10(45.5%) | 6(27.2%) | |
| > 5 cm | 36(30.0%) | 10(27.8%) | 17(47.2%) | 19(25.0%) | |
| PVTT | 0.005** | ||||
| Absent | 58(64.4%) | 9(15.5%) | 31(53.4%) | 18(31.1%) | |
| Present | 32(35.6%) | 12(37.5%) | 13(40.6%) | 7(21.9%) | |
| Differentiation | 0.026* | ||||
| Well | 9(10.0%) | 3(33.3%) | 1(11.1%) | 5(55.6%) | |
| Moderate | 45(50.0%) | 5(11.1%) | 27(60.0%) | 13(28.9%) | |
| Poor | 36(40.0%) | 13(36.1%) | 16(44.4%) | 7(19.5%) | |
| TNM Stage | 0.011* | ||||
| Ⅰ | 56(62.2%) | 6(10.7%) | 32(57.1%) | 18(32.2%) | |
| Ⅱ | 20(22.2%) | 11(55.0%) | 5(25.0%) | 4(20.0%) | |
| Ⅲ-Ⅳ | 14(15.6%) | 4(28.6%) | 7(50.0%) | 3(21.4%) | |
*P<0. 05, **P<0.01.
Abbreviations: GSTA1: Glutathione S-transferase A1. HBsAg: hepatitis B surface antigen. AFP: alpha-fetoprotein. PVTT: portal vein tumor thrombosis. TNM: tumor-node-metastasis.